pandemic influenza vaccine h5n1 astrazeneca (previously pandemic influenza vaccine h5n1 medimmune)
astrazeneca ab - reassortant influenza virus (live attenuated) of the following strain: a/vietnam/1203/2004 (h5n1) strain - influenza, human - vaccines - prophylaxis of influenza in an officially declared pandemic situation in children and adolescents from 12 months to less than 18 years of age.pandemic influenza vaccine h5n1 astrazeneca should be used in accordance with official guidance
unistrain prrs lyophilisate and solvent for suspension for injection for pigs
laboratorios hipra s.a. - live attenuated prrsv, strain vp-046 bis - lyophilisate and solvent for suspension for injection - 10(3.5) - 10(5.5) cell culture infective dose 50/dose - porcine reproductive and respiratory syndrome (prrs) virus - pigs - immunological - live vaccine
poulvac ib qx lyophilisate for oculonasal suspension for chickens
zoetis belgium s.a. - live attenuated avian infectious bronchitis virus strain l1148 - lyophilisate for suspension for spray administration - . 50% embryo infective dose/dose - avian infectious bronchitis virus - chickens - immunological - live vaccine
levetiracetam extended-release- levetiracetam tablet, film coated, extended release
par pharmaceutical, inc. - levetiracetam (unii: 44yrr34555) (levetiracetam - unii:44yrr34555) - extended-release levetiracetam tablets are indicated as adjunctive therapy in the treatment of partial onset seizures in patients 12 years of age and older with epilepsy. extended-release levetiracetam tablets are contraindicated in patients with a hypersensitivity to levetiracetam. reactions have included anaphylaxis and angioedema [see warnings and precautions (5.4) ]. extended-release levetiracetam tablets levels may decrease during pregnancy [see warnings and precautions (5.9) ]. pregnancy category c there are no adequate and well-controlled studies in pregnant women. in animal studies, levetiracetam produced evidence of developmental toxicity, including teratogenic effects, at doses similar to or greater than human therapeutic doses. extended-release levetiracetam tablets should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus. oral administration of levetiracetam to female rats throughout pregnancy and lactation led to increased incidences of minor fetal
zoonotic influenza vaccine seqirus
seqirus s.r.l. - zoonotic influenza vaccine (h5n1) (surface antigen, inactivated, adjuvanted), influenza virus surface antigens (haemagglutinin and neuraminidase) of strain: a/turkey/turkey/1/05 (h5n1)-like strain (nibrg-23) - influenza a virus, h5n1 subtype - vaccines - active immunisation against h5 subtype of influenza a virus
teva-levetiracetam tablet
teva canada limited - levetiracetam - tablet - 250mg - levetiracetam 250mg - miscellaneous anticonvulsants
teva-levetiracetam tablet
teva canada limited - levetiracetam - tablet - 500mg - levetiracetam 500mg - miscellaneous anticonvulsants
teva-levetiracetam tablet
teva canada limited - levetiracetam - tablet - 750mg - levetiracetam 750mg - miscellaneous anticonvulsants
apo-levetiracetam tablet
apotex inc - levetiracetam - tablet - 250mg - levetiracetam 250mg - miscellaneous anticonvulsants
apo-levetiracetam tablet
apotex inc - levetiracetam - tablet - 500mg - levetiracetam 500mg - miscellaneous anticonvulsants